Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 6/20 | 0.54 |
| ▸ | FADS1 | O60427 | 5/20 | 0.51 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8501013 | 0.86 | FADS1 (0.53) | GRM2FADS1MAOAMAOBPOLB | |
| SCHEMBL27576681 | 0.83 | GRM2 (0.53) | GRM2FADS1MAOAMAOBPOLB | |
| SCHEMBL6612471 | 0.83 | FADS1 (0.57) | GRM2FADS1MAOAMAOBPOLB | |
| SCHEMBL8502311 | 0.77 | GRM2 (0.51) | GRM2FADS1MAOAMAOBPOLB | |
| SCHEMBL6644912 | 0.77 | GRM2 (0.65) | GRM2FADS1MAOAMAOBPOLB | |
| SCHEMBL27576680 | 0.76 | GRM2 (0.70) | GRM2FADS1MAOAMAOB | |
| SCHEMBL8503717 | 0.73 | FADS1 (0.64) | GRM2FADS1MAOAMAOBPOLB | |
| SCHEMBL1032517 | 0.73 | MAOA (0.71) | GRM2FADS1MAOAMAOB | |
| SCHEMBL1557298 | 0.73 | MAOA (0.71) | GRM2FADS1MAOAMAOB | |
| SCHEMBL3087781 | 0.73 | MAOA (0.71) | GRM2FADS1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6689779-B2 | PYRIDINE OR PYRIMIDINE SUBSTITUTED; ANTIBACTERIAL ACTIVITY; LOW TOXICITY | DONG A PHARM. CO., LTD. (KR) | 2004-02-10 | — | — | US | disclosed |
| US-20030166620-A1 | Novel oxazolidinone derivatives and a process for the preparation thereof | DONG A PHARM. CO., LTD. (KR) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166620-A1 | Novel oxazolidinone derivatives and a process for the preparation thereof | OXA1L, ODC1, PDCD4 | GRM2 4033/4885FADS1 3702/4885MAOA 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.